TibaRay's Revolutionary Galactica Cancer Treatment Moves Toward Clinical Reality

A Leap Towards Innovative Cancer Care

TibaRay, a pioneering medical technology firm born out of research from Stanford University, is setting a new course in cancer treatment. On July 9, 2026, the company proudly announced that it has officially begun manufacturing its first Galactica™ cancer treatment systems. This significant step forward is not just a milestone for TibaRay but a crucial advancement for patients who rely on radiotherapy as part of their cancer care journey.

The Galactica system represents a remarkable integration of cutting-edge technology and patient comfort. Unlike traditional radiotherapy platforms where patients lie down, the Galactica system allows patients to be treated while sitting or standing. This innovative approach aims to enhance patient comfort, providing a more hopeful treatment experience while focusing on the delicate nature of cancer care.

Historically, radiotherapy has been a critical part of cancer treatment, benefiting nearly two-thirds of all cancer patients. However, many healthcare providers are still dependent on outdated technologies, such as large linear accelerators that come with their own set of drawbacks: high costs, cumbersome installation, and precision limitations. Thinh Tran, the CEO of TibaRay, expressed this frustration, stating, “For years, our team has focused on solving radiation oncology's biggest challenge: making treatment more precise and accessible for more patients.”

With the entry into manufacturing, the Galactica is no longer just an idea; it is becoming a tangible reality. This groundbreaking technology is designed to streamline the complexities often associated with traditional treatment systems, thus transforming years of research and engineering into practical applications ready for clinical deployment.

Built on accelerator technologies initially developed at Stanford, TibaRay’s system is the first significant evolution in medical linear accelerators in nearly seven decades. The proprietary technology generates high-energy X-rays for precise cancer treatment within a device that is smaller and more efficient than its predecessors. The Galactica system is not only about enhancing the current paradigm of cancer treatment; it lays the groundwork for a promising future option known as FLASH therapy. Researchers posit that FLASH has the capacity to eliminate tumors while simultaneously minimizing harm to surrounding healthy tissue, due to its remarkable delivery speed of radiotherapy.

As TibaRay heads toward clinical implementation, the company is gearing up for the installation of these advanced systems. An exciting initial deployment is scheduled for later this year at Mayo Clinic, a testament to the collaborative efforts between innovative medical technology and top-tier healthcare institutions.

The ambition of TibaRay extends far beyond the invention of a new treatment machine. Their vision is rooted in enhancing patient experiences, ensuring treatments are faster, more precise, and ultimately more accessible to cancer patients globally. With the Galactica system at the forefront, TibaRay stands committed to its mission of Curing Cancer in a FLASH™.

For further insights into TibaRay’s advancements in medical technology and the Galactica system, interested individuals are encouraged to visit TibaRay.com. With ongoing developments in cancer treatment through innovation and dedication, TibaRay is poised to reshape the landscape of oncology and eradicate barriers for patients facing cancer.